Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Post time 2024-5-10 00:58:53

journal：European Endocrinology

Authors：Gres Karim; Meena B Bansal; ;

Published date：2023--

DOI：10.17925/ee.2023.19.1.60

Article link：http://dx.doi.org/10.17925/ee.2023.19.1.60

Article Source：Touch Medical Media, Ltd.。

Remark：

Post time 2024-5-10 00:58:54

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Other] Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis

Best Answer

Viewed forums

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis Copy